Ototoxicity and Teprotumumab.

Julie HighlandSteven GordonDeepika ReddyNeil Patel

Published in: The Annals of otology, rhinology, and laryngology (2021)

This is one of the first descriptive cases of ototoxicity resulting in irreversible sensorineural hearing loss in the setting of treatment with teprotumumab. Periodic audiologic evaluations should be recommended to patients on teprotumumab.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
cross sectional
combination therapy